anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND/OBJECTIVES: Urinary tract infections (UTIs) represent a substantial health concern worldwide. Although it is known that the gut can act as a reservoir for UTI-causing pathogens, the exact role of the gut microbiome in developing UTIs remains unclear. This review aims to investigate the link between the gut microbiome and UTIs and whether gut dysbiosis increases the risk of getting a UTI.
METHODS: To find relevant studies, a search was conducted across three databases, PubMed, EMBASE and Cochrane Library. Only records that directly described the association between the gut microbiome and UTIs were included in this review.
RESULTS: Of the numerous studies retrieved, eight studies met the pre-set criteria and were selected for the review. The findings suggest several potential ways in which gut dysbiosis might enhance UTI susceptibility. A low gut microbiome diversity, a reduced level of bacteria involved in short-chain fatty acid (SCFA) production and a high abundance of Escherichia coli (E. coli) among UTI patients all offer a reasonable explanation for the existence of a link between an altered gut microbiome and UTIs. However, contradictory study results make it difficult to verify this.
CONCLUSIONS: Research on the link between the gut microbiome and UTIs is limited, and further studies need to be carried out to substantiate this relationship, as this can bring attention to finding improved and more relevant treatment for UTIs.
The invention discloses a Chinese medicinal composition and a method for treating diseases related to both the liver meridian and the large intestine meridian. The medicinal composition comprises 2 g of Angelica officinalis, 3 g of Semen Cassiae, 3 g of Cortex Fraxini, 3 g of Thalictrum foliolosum, 3 g of Rhizoma Bistortae, 3 g of Sargentodoxa cuneata, 3 g of Rhizome Picrorhizae, 3 g of pine nut kernels, 2 g of Clerodendron trichotomum, 2 g of Officinal magnolia, 3 g of Swertia pseudochinensis, 2 g of Piper longum, 2 g of Pericarpium Citri Reticulatae Viride, 3 g of Fructus Bruceae, 3 g of Sophora japonica flower, 2 g of Rhizoma Corydalis decumbentis, 1 g of Semen Persicae, 2 g of Scaphium wallichii, 2 g of Hyoscyamus niger, 2 g of pearl, 2 g of honey, 2 g of Songaria cynomorium, 2 g of ferrous sulfate, and 3 g of black sesame seed. The acupoints for disease treatment include Xingjian acupoint, Taicong acupoint, Ligou acupoint, Xiguan acupoint, Yinbao acupoint, Zuwuli acupoint, Qimen acupoint, Erjian acupoint, Sanjian acupoint, Yangxi acupoint, Wenliu acupoint, Zhouliao acupoint, Jjianyu acupoint and Yingxiang acupoint. The auxiliary devices include a barrel for holding excretions, a barrel for holding Chinese medicines, an auxiliary barrel, an ozone generator, and an ultrasonic generator for excretions. The auxiliary items include purified water, Angelica officinalis, and Ailanthus Altissima bark. The composition and method can be used for treating diseases related to both the liver meridian and the large intestine meridian, and is applied in clinic.
BACKGROUND: Migraine is one of the most common primary headaches worldwide, while toothache is the most common pain in the orofacial region. The association of migraine pain, and oral pain is unknown. This study aims to investigate the association between migraine and dental and gingival pain with the presence of allodynia.
METHODS: A questionnaire comprising demographic data with the ID-Migraine (IDM) tool, an Allodynia Symptom Checklist (ASC), and inquiries about pain and sensitivity in the teeth and gums during migraine attacks was administered to the participants and 762 responded the survey. The study classified participants based on the ASC, and the relationship between allodynia and pain/sensitivity in the teeth and/or gums during migraine attacks was analyzed. The statistical analyses utilized Chi-square tests and the Fisher-Exact test.
RESULTS: Among 762 migraine patients, 430 (56.44%) were classified as allodynia (+), while 332 (43.56%) were classified as allodynia (-) (p < 0.001). Additionally, 285 participants (37.5%) reported experiencing pain and sensitivity in the teeth and gums during migraine attacks, with a significant relationship observed between allodynia and pain/sensitivity in the teeth and/or gums during migraine attacks (p < 0.001).
CONCLUSION: The findings of this study have important clinical implications. For migraine patients who are non-allodynic, the presence of pain and sensitivity in their teeth and gums during migraine attacks may indicate underlying dental diseases or the need for dental treatment especially root canal treatment. However, for allodynic patients, such symptoms may not necessarily indicate the presence of dental diseases or the need for dental treatment especially root canal treatment. These results underscore the significance of considering the presence of allodynia in the assessment and management of oral symptoms during migraine attacks.
BACKGROUND: Non-communicable diseases account for nearly three-fourths of global deaths impacting public health and development. Coexisting diseases can complicate the management of surgical diseases, increasing the risk of perioperative mortality. Despite this, few studies have examined the burden of comorbidities among surgical patients and their effect on perioperative outcomes in low-income countries. In this study, we assessed the impact of comorbidity burden on 28-day perioperative mortality using a prospective data set.
METHODS: This was a facility-based prospective cohort study. Adult patients aged ≥ 18 who underwent non-cardiac surgery were included. Patients were followed for 28 days following surgery. Perioperative data were collected using an electronic data collection system from June 01, 2019, to June 30, 2021, at Tibebe Ghion Specialized Hospital, Northwest, Ethiopia. A propensity score-matched analysis was employed to assess the effect of comorbidity on the 28-day perioperative mortality rate.
RESULTS: Of the 3030 patients included in this study, 715 (23.59%) had at least one comorbidity. Based on the prevalence rate, the top four comorbid conditions observed were hypertension (0.050), cancer (0.036), diabetes mellitus (0.021), and human immunodeficiency virus (0.021). The 28-day perioperative mortality rate was shown to be significantly higher among patients with comorbidity, where 45 (6.29%) of the 715 patients with comorbidity died compared to 49 (2.12%) of the 2315 patients with no comorbidity (p-value < 0.0001). After propensity score matching potential confounders, patients who have comorbidity had a 2.52% (average treatment effect on treated (ATT) = 0.0252) higher risk of perioperative death at 28 days after surgery compared with patients who did not have comorbidity.
CONCLUSION: This study found a moderate prevalence of comorbid illnesses among non-cardiac surgical patients, with comorbidity increasing the risk of 28-day perioperative mortality. Preoperative screening and optimization are highly recommended for patients with comorbid illness to decrease perioperative mortality rate.
Because it is poorly understood, the treatment of wrist arthritis remains limited to suboptimal salvage operations and wrist fusions. These are surgeries, which greatly limit function. This study is designed to evaluate arthritis of the STT joint and its affect on arthritis in other parts of the wrist. This may improve the understanding of wrist mechanics enabling us to develop better treatment of wrist arthritis. STT joint arthrodesis is an accepted surgery whose indications may be influenced by information obtained in this study.

Five patients being treated by the PI that have a diagnosis or a finding of STT joint arthritis stage 3 on X-ray will be included in the study. The radiographs are standard of care for various hand and wrist conditions and patients will be sent for radiographs only as part of their care. The patients will be eligible for the study following informed consent. The CT scan will be performed at 5-7 wrist positions: neutral, maximum extension, flexion, radial deviation, ulnar deviation (plus radial extension and ulnar flexion for 7 positions). Slice thickness will be less than 1 mm. The slices will be located between distal radioulnar joint (DRUJ) and the 2nd carpometacarpal (CMC) joint. The CT scans will then be sent for evaluation by the computer based kinematic program. No identifiable information will be collected or recorded. The program will develop a kinematic model of the STT joint in the presence of arthritis.

The model (kinematic data) will be compared to an existent "normal" model, based on 7 CT scans of normal STT joints. This data is already in existence and therefore no normal wrists are accrued.
The invention relates to an implantable active ingredient depot for therapeutically active substances. The fields of application are in medicine and the pharmaceutical industry. The implantable active ingredient depot is constituted of a lipid matrix capable of forming cubic phases into which modifier molecules have been integrated and contains pharmaceutically active substances. A preferred lipid matrix is monooleine. The implantable depot of the invention is useful for the treatment of tumors in oncological therapy and in gene therapy. A rational membrane design allows control of the release of the active ingredients over time and also control of the amount released.
The present invention relates to the treatment of myopathy. The inventors report the identification of effective AS-siRNA against the two nucleotide versions of the two non- pathogenic DNM2 SNPs which may be used to silence any mutation carried by the same mRNA. In addition, the first AS-siRNAs targeting a DNM2 mutation associated with severe neonatal phenotype, i.e. the p.S619L mutation, have been developed and in a second time, they developed other AS-siRNA targeting the mutation p.S619L and the mutation p.R465W. They also report the functional benefits of this new set of siRNAs on several defects identified in patient-derived cell lines. The development of these new AS-siRNA, in addition to the previous ones against the p.R465W mutation, provides a panoply of allele-specific molecules able to target the large majority of AD-CNM patients. Interestingly, siRNAs against the DNM2 SNPs represent versatile molecules with larger potential applications to silence DNM2 mutations in CMT and HSP and to reduce DNM2 expression in a controlled manner in diseases associated with deleterious overexpression. Thus, the present invention relates to an allele specific siRNA (AS-siRNA) able to silence the expression of only one allele of a heterozygous DNM2 gene wherein the targeted allele comprises a non-pathological polymorphism selected from the group consisting of rs2229920 (C or T) or rs12461992 (A or T) and/or a disease-causing mutation selected from the group consisting of c.1393C>T or c.1856C>T.
Eligible participants will take part in the RAWBONE sailing program, which will utilize dinghies with universal design known for their exceptional stability to prioritize safety. The instructor-to-participant ratio will be 1:6, with each participant accompanied by a volunteer on a 1:1 ratio, and a safety boat present. The program will conclude with participants receiving a certificate of participation. Participants will receive a social skills booklet that is identical to the placebo received by the control group.
Trainees will be taught the following skills during a single session: 1) Therapist in-session emotional-awareness and self-regulation; 2) Facilitating client disclosure of traumas and other difficult experiences; and 3) Helping clients access and experience adaptive emotions. In the standard training condition, the trainee will receive a lecture about the skills including rationale and research background, examples, and opportunities to ask questions. The standard training condition will not include opportunities for practice or live discussion and feedback from the trainer.
The participants in EA group will receive acupuncture with PSD at bilateral Hegu (LI4), bilateral Quchi (LU5), bilateral Xuehai (SP10) and bilateral San Yinjiao (SP6). After skin disinfection, followed at an angle of 90°, acupuncture needles were inserted approximately 50 to 60 mm into the skin. When achieving qi, connect the four pairs of electrodes, two each on bilateral Quchi (LI4) and Hegu (LI11), two each on bilateral Xuehai (SP10) and San Yinjiao (SP6), and they are all ipsilateral to one another. The duration of the electroacupuncture stimulation is 30 minutes, and the current intensity ranges from 1 to 5 mA with a continuous wave of 20 Hz. For two weeks straight, the participants will have three therapy sessions each week (preferably every other day), for a total of six sessions.
Periodontal disease is a chronic state of inflammation that can destroy the supporting tissues around the teeth, leading to a loss of connective tissue and the periodontal ligament, the resorption of alveolar bone and eventual tooth loss. Periodontal disease can also induce dysbiosis in the gut microbiome and contribute to low grade systemic inflammation. Prebiotic fibres such as inulin can selectively alter the intestinal microbiota to bring back a state of homeostasis by improving gut barrier functions and preventing inflammation. Through this mechanism, supplementation with inulin may be able to indirectly benefit periodontal health. The primary objective of this trial to determine if inulin supplementation, provided pre-sanative therapy (ST) through the healing phase (post-ST) is more effective than the placebo at improving clinical outcomes of periodontal health: decreasing both the number of sites with probing depths greater than or equal to 4 mm and increasing the absence of bleeding on probing (BOP). Secondary objectives include determining the effects of inulin supplementation pre- and post-ST on salivary markers of inflammation and periodontal-associated pathogens.
The present invention belongs to a food, which is a sobering-up oral liquid. The sobering-up oral liquid is prepared through the following steps: preparing chrysanthemum flowers, pueraria roots, alpiniae oxyphyllae, polygala roots, alismatis and licorice roots according to raw material proportion, cleaning, putting into a pot, repeatedly decocting for 2 to 3 times with water, collecting decoction, filtering and centrifugal separating the decoction for removing fine particles and foreign matters, obtaining medicine pulp by concentration according to 10: 1, proportioning the honey into syrup, mixing the medicine pulp and the syrup and stirring in uniformity. The sobering-up oral liquid of the present invention has the functions of tranquilization, heat radiation, dryness removal, gallbladder protection, water removal and dehumidification. The sobering-up oral liquid has especially obvious sobering up and detoxification effects on people drinking excess wines. The product of the present invention has the advantages of less dosage, portability, good taste and good market prospect. The present invention is particularly preferred by alcoholist and welcomed by mass, and has a constant consumption group.
Infection processes of a non-typhoid Salmonella infection in humans are not well understood and so far, only little research has been conducted in this area. Findings from preclinical studies, using mouse models, attributed a fundamental role in infection control to the gut microbiota and the host immune system (antibody response). In mouse models a non-typhoid Salmonella infection provokes a pronounced antibody response and salmonella-inflicted gut inflammation alters the microbiota diversity and composition in the gut lumen. To date there is only scarce evidence on similar effects in humans.

During the study, longitudinal stool and blood samples will be collected from patients with a non-typhoid Salmonella infection at different study time points (2 weeks, 4 weeks and 6 months after positive Salmonella stool culture) and analyzed for changes in the microbiota, mutation rates in the Salmonella strains and the specific immune response evoked by the infection (e.g. anti-bodies). At each study time point clinical information will be investigated with a questionnaire to assess current symptoms, medication etc. Findings will be compared to healthy individuals and patients with acute, infectious diarrhea caused by other microorganisms than non-typhoid Salmonella.
The invention discloses a retrotransposon gene L1-FGGY and application thereof as a lung squamous carcinoma marker. The nucleic acid sequence of the retrotransposable gene L1-FGGY is SEQ ID NO. 1. The upstream detection primer nucleic acid sequence of the reverse transcription transposition gene L1-FGGY is SEQ ID NO. 2; the downstream detection primer has the nucleic acid sequence of SEQ ID NO. 3. The reverse transcription transposition inhibitor nevirapine or efavirenz can inhibit the expression level of a reverse transcription transposition gene L1-FGGY, and is used for treating squamous cell lung carcinoma. The L1-FGGY reverse transcription transposition gene disclosed by the invention can be used as a new tumor marker, the detection of L1-FGGY can be used for early diagnosis, molecular typing and prognosis evaluation of squamous cell lung carcinoma, and meanwhile, L1-FGGY can also be a potential treatment target, so that the L1-FGGY reverse transcription transposition gene is applied to clinical treatment of squamous cell lung carcinoma and has wide application prospect.
Patients who developed complications during EBUS-TBNA. Patients may experience intraoperative complications (bleeding, hypoxemia, hypotension, arrhythmia, bronchospasm, pneumothorax, subcutaneous emphysema/mediastinal emphysema, respiratory depression), and postoperative complications (bleeding, pneumonia, respiratory failure, atelectasis, pleural effusion/empyema, pulmonary embolism, pulmonary edema). Complications that develop (such as acute respiratory distress syndrome, delirium, and mortality) will be recorded. After the procedure, any complications that may develop in the patients within 30 days will be questioned and recorded.
Provided is a kit or system ( 100 ) for preparing a peroxide composition with increased viscosity with a pH in the range of 7 to 12 in an almost instantaneous method. For example, the kit or system may be used to provide an almost instantly obtainable (hydro)gelled peroxide composition. The system comprises a first aqueous composition ( 102 ) comprising a peroxide agent. The first aqueous composition has a first pH of less than 7. The system further comprises a second composition ( 104 ) comprising a basic agent. The second composition is separate from the first aqueous composition. A pH induced thickener is included in the kit or system separate from the second composition. The peroxide composition is obtainable by combining the parts of the kit or system. The pH induced thickener is capable of increasing the viscosity of the peroxide composition upon subjecting it to the pH in the range of 7 to 12. The kit or system has sufficient basic agent for the peroxide composition to cause the pH in the range of 7 to 12. A method for preparation and use of the kit or system is also provided.
INTRODUCTION: Rectal prolapse is prevalent in children and the elderly, impacting quality of life significantly. Traditional surgical interventions carry risks, especially in pediatric patients. Ethanol sclerotherapy offers a less invasive alternative, inducing fibrosis and thickening of the rectal wall. Despite its potential benefits, procedural complications are possible, emphasizing the need for careful patient selection and procedural expertise. This study aims to evaluate the safety and efficacy of sclerotherapy in treating rectal prolapse in a tertiary referral center in southern Iran.
METHODS: Patient records from Nemazee Hospital covering January 2014 to December 2023 were retrospectively analyzed. Pediatric patients undergoing ethanol sclerotherapy for rectal prolapse were included. Data on demographics, presentation, procedures, and outcomes were collected. Ethical approval was obtained, and specific inclusion/exclusion criteria were applied. Statistical analyses were conducted using SPSS version 26.
RESULTS: One hundred thirty patients were evaluated, with a mean age of 10.74 ± 5.320 years. Most patients experienced constipation (56.9%). 74.2% responded well to sclerotherapy, with 12.9% needing a second injection. Complications were minimal, with bleeding being the most common (4.6%). Recurrence occurred in 18.6% of cases. Male patients showed a higher total complication rate (P = 0.010). Diarrhea-dominant patients had no recurrences post-sclerotherapy. Age significantly influenced treatment response and recurrence (P = 0.017, P = 0.035).
CONCLUSION: Male predominance contradicted global pediatric rectal prolapse ratios, possibly influenced by cultural factors. Sclerotherapy remains effective, though response rates vary. Older age correlated with lower response rates and higher recurrence. Constipation-dominant prolapse was associated with increased recurrence risk. Male patients had a higher complication rate, highlighting the need for tailored management strategies.
Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder, yet its underlying causes remain elusive. The conventional perspective on disease pathogenesis attributes alterations in neuronal excitability to molecular changes resulting in synaptic dysfunction. Early hyperexcitability is succeeded by a progressive cessation of electrical activity in neurons, with amyloid beta (Aβ) oligomers and tau protein hyperphosphorylation identified as the initial events leading to hyperactivity. In addition to these key proteins, voltage-gated sodium and potassium channels play a decisive role in the altered electrical properties of neurons in AD. Impaired synaptic function and reduced neuronal plasticity contribute to a vicious cycle, resulting in a reduction in the number of synapses and synaptic proteins, impacting their transportation inside the neuron. An understanding of these neurophysiological alterations, combined with abnormalities in the morphology of brain cells, emerges as a crucial avenue for new treatment investigations. This review aims to delve into the detailed exploration of electrical neuronal alterations observed in different AD models affecting single neurons and neuronal networks.
A pilot randomized, sham-controlled clinical trial will be conducted in participants with IBS to achieve the following aims: Aim 1-collect preliminary data assessing the clinical impact of VR cognitive behavioral therapy (CBT) (SynerGI); Aim 2-establish the feasibility of using an 8-week VR CBT program among patients with IBS. The study will follow the established NIH protocol for conducting VR clinical trials, which aligns with VR-CORE clinical trial guidance. Participants will be randomized in a 1:1 ratio between two arms : (i) immersive VR CBT Program (SynerGI); and (ii) sham VR. As a pilot randomized controlled trial, it will not be powered for hypothesis testing of clinical outcomes . Instead, the focus will be on determining the plausibility and feasibility of SynerGI, with the aim to recruit 30 fully analyzable patients per arm.

Patients will be randomized 1:1 to each study arm . Block randomization will be implemented, using random permuted block sizes of 6, 8, or 10, allowing for up to 15% additional participants beyond the original sample size to account for dropouts. Randomization will also be stratified by sex to ensure a balance of women and men in each arm. Assessments will take place at baseline, midway through therapy at 4 weeks, and after completing the program at 8 weeks (a standard treatment length for VR trials).